Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Pharmacol Ther. 2024 Oct;262:108698. doi: 10.1016/j.pharmthera.2024.108698. Epub 2024 Aug 3.
Melanoma is the deadliest form of skin cancer in the United States, with its incidence rates rising in older populations. As the immune system undergoes age-related changes, these alterations can significantly influence tumor progression and the effectiveness of cancer treatments. Recent advancements in understanding immune checkpoint molecules have paved the way for the development of innovative immunotherapies targeting solid tumors. However, the aging tumor microenvironment can play a crucial role in modulating the response to these immunotherapeutic approaches. This review seeks to examine the intricate relationship between age-related changes in the immune system and their impact on the efficacy of immunotherapies, particularly in the context of melanoma. By exploring this complex interplay, we hope to elucidate potential strategies to optimize treatment outcomes for older patients with melanoma, and draw parallels to other cancers.
黑色素瘤是美国最致命的皮肤癌形式，其发病率在老年人群中上升。随着免疫系统发生与年龄相关的变化，这些改变会显著影响肿瘤的进展和癌症治疗的效果。近年来，人们对免疫检查点分子的理解有了新的进展，为开发针对实体瘤的创新免疫疗法铺平了道路。然而，衰老的肿瘤微环境在调节对这些免疫治疗方法的反应方面起着至关重要的作用。本综述旨在探讨免疫系统与年龄相关变化之间的复杂关系及其对免疫疗法疗效的影响，特别是在黑色素瘤方面。通过探索这种复杂的相互作用，我们希望阐明为老年黑色素瘤患者优化治疗效果的潜在策略，并与其他癌症进行类比。
